[1] Wright S, Hashemi K, Stasiak L, Bartram J, Lang B, Vincent A, Upton AL. Epileptogenic effects of NMDAR antibodies in a passive transfer mouse model[J]. Brain, 2015, 138(Pt 11):3159-3167. [2] Ohkawa T, Fukata Y, Yamasaki M, Miyazaki T, Yokoi N, Takashima H, Watanabe M, Watanabe O, Fukata M. Autoantibodies to epilepsy-related LGI1 in limbic encephalitis neutralize LGI1-ADAM22 interaction and reduce synaptic AMPA receptors[J]. J Neurosci, 2013, 33:18161-18174. [3] Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L, Hirsch E, Jain S, Mathern GW, Moshé SL, Nordli DR, Perucca E, Tomson T, Wiebe S, Zhang YH, Zuberi SM. ILAE classification of the epilepsies:position paper of the ILAE Commission for Classification and Terminology[J]. Epilepsia, 2017, 58:512-521. [4] Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T, Cortese I, Dale RC, Gelfand JM, Geschwind M, Glaser CA, Honnorat J, Höftberger R, Iizuka T, Irani SR, Lancaster E, Leypoldt F, Prüss H, Rae-Grant A, Reindl M, Rosenfeld MR, Rostásy K, Saiz A, Venkatesan A, Vincent A, Wandinger KP, Waters P, Dalmau J. A clinical approach to diagnosis of autoimmune encephalitis[J]. Lancet Neurol, 2016, 15:391-404. [5] Neuroinfectious Diseases and Cerebrospinal Fluid Cytology Group, Neurology Branch, Chinese Medical Association. Chinese expert consensus on the diagnosis and management of autoimmune encephalitis (2022 edition)[J]. Zhonghua Shen Jing Ke Za Zhi, 2022, 55:931-949[.中华医学会神经病学分会神经感染性疾病与脑脊液细胞学学组. 中国自身免疫性脑炎诊治专家共识(2022年版)[J]. 中华神经科杂志, 2022, 55:931-949.] [6] Guo K, Liu X, Lin J, Gong X, Li A, Liu Y, Zhou D, Hong Z. Clinical characteristics, long-term functional outcomes and relapse of anti-LGI1/Caspr2 encephalitis:a prospective cohort study in western China[J]. Ther Adv Neurol Disord, 2022, 15: 17562864211073203. [7] Irani SR, Alexander S, Waters P, Kleopa KA, Pettingill P, Zuliani L, Peles E, Buckley C, Lang B, Vincent A. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia[J]. Brain, 2010, 133:2734-2748. [8] Rodriguez A, Klein CJ, Sechi E, Alden E, Basso MR, Pudumjee S, Pittock SJ, McKeon A, Britton JW, Lopez-Chiriboga AS, Zekeridou A, Zalewski NL, Boeve BF, Day GS, Gadoth A, Burkholder D, Toledano M, Dubey D, Flanagan EP. LGI1 antibody encephalitis:acute treatment comparisons and outcome[J]. J Neurol Neurosurg Psychiatry, 2022, 93:309-315. [9] Celicanin M, Blaabjerg M, Maersk-Moller C, Beniczky S, Marner L, Thomsen C, Bach FW, Kondziella D, Andersen H, Somnier F, Illes Z, Pinborg LH. Autoimmune encephalitis associated with voltage-gated potassium channels-complex and leucine-rich glioma-inactivated 1 antibodies:a national cohort study[J]. Eur J Neurol, 2017, 24:999-1005. [10] van Sonderen A, Thijs RD, Coenders EC, Jiskoot LC, Sanchez E, de Bruijn MA, van Coevorden-Hameete MH, Wirtz PW, Schreurs MW, Sillevis Smitt PA, Titulaer MJ. Anti-LGI1 encephalitis:clinical syndrome and long-term follow-up[J]. Neurology, 2016, 87:1449-1456. [11] Steriade C, Moosa ANV, Hantus S, Prayson RA, Alexopoulos A, Rae-Grant A. Electroclinical features of seizures associated with autoimmune encephalitis[J]. Seizure, 2018, 60:198-204. [12] Chengyu L, Weixiong S, Chao C, Songyan L, Lin S, Zhong Z, Hua P, Fan J, Na C, Tao C, Jianwei W, Haitao R, Hongzhi G, Xiaoqiu S. Clinical features and immunotherapy outcomes of anti-glutamic acid decarboxylase 65 antibody-associated neurological disorders [J]. J Neuroimmunol, 2020, 345:577289. [13] Lv RJ, Ren HT, Guan HZ, Cui T, Shao XQ. Seizure semiology:an important clinical clue to the diagnosis of autoimmune epilepsy[J]. Ann Clin Transl Neurol, 2018, 5:208-215. [14] Uy CE, Binks S, Irani SR. Autoimmune encephalitis:clinical spectrum and management[J]. Pract Neurol, 2021, 21:412-423. [15] Muñiz-Castrillo S, Haesebaert J, Thomas L, Vogrig A, Pinto AL, Picard G, Blanc C, Do LD, Joubert B, Berzero G, Psimaras D, Alentorn A, Rogemond V, Dubois V, Ambati A, Tamouza R, Mignot E, Honnorat J. Clinical and prognostic value of immunogenetic characteristics in anti-LGI1 encephalitis[J]. Neurol Neuroimmunol Neuroinflamm, 2021, 8:e974. [16] Lai M, Huijbers MG, Lancaster E, Graus F, Bataller L, Balice-Gordon R, Cowell JK, Dalmau J. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels:a case series[J]. Lancet Neurol, 2010, 9:776-785. [17] Teng Y, Li T, Yang Z, Su M, Ni J, Wei M, Shi J, Tian J. Clinical features and therapeutic effects of anti-leucine-rich glioma inactivated 1 encephalitis:a systematic review[J]. Front Neurol, 2022, 12:791014. [18] Irani SR, Michell AW, Lang B, Pettingill P, Waters P, Johnson MR, Schott JM, Armstrong RJ, S Zagami A, Bleasel A, Somerville ER, Smith SM, Vincent A. Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis[J]. Ann Neurol, 2011, 69:892-900. [19] Flanagan EP, Kotsenas AL, Britton JW, McKeon A, Watson RE, Klein CJ, Boeve BF, Lowe V, Ahlskog JE, Shin C, Boes CJ, Crum BA, Laughlin RS, Pittock SJ. Basal ganglia T1 hyperintensity in LGI1-autoantibody faciobrachial dystonic seizures[J]. Neurol Neuroimmunol Neuroinflamm, 2015, 2:e161. [20] Smith KM, Dubey D, Liebo GB, Flanagan EP, Britton JW. Clinical course and features of seizures associated with LGI1-antibody encephalitis[J]. Neurology, 2021, 97:e1141-1149. [21] Zhong R, Chen Q, Zhang X, Zhang H, Lin W. Relapses of anti-NMDAR, anti-GABABR and anti-LGI1 encephalitis:a retrospective cohort study[J]. Front Immunol, 2022, 13:918396. [22] Kaaden T, Madlener M, Angstwurm K, Bien CG, Bogarin Y, Doppler K, Finke A, Gerner ST, Reimann G, Häusler M, Handreka R, Hellwig K, Kaufmann M, Kellinghaus C, Koertvelyessy P, Kraft A, Lewerenz J, Menge T, Paliantonis A, von Podewils F, Prüss H, Rauer S, Ringelstein M, Rostásy K, Schirotzek I, Schwabe J, Sokolowski P, Suesse M, Sühs KW, Surges R, Tauber SC, Thaler F, Bergh FT, Urbanek C, Wandinger KP, Wildemann B, Mues S, Zettl U, Leypoldt F, Melzer N, Geis C, Malter M, Kunze A; the Generate Study Group. Seizure semiology in antibody-associated autoimmune encephalitis[J]. Neurol Neuroimmunol Neuroinflamm, 2022, 9:e200034. [23] Navarro V, Kas A, Apartis E, Chami L, Rogemond V, Levy P, Psimaras D, Habert MO, Baulac M, Delattre JY, Honnorat J; Collaborators. Motor cortex and hippocampus are the two main cortical targets in LGI1-antibody encephalitis[J]. Brain, 2016, 139(Pt 4):1079-1093. [24] Chen C, Wang X, Zhang C, Cui T, Shi WX, Guan HZ, Ren HT, Shao XQ. Seizure semiology in leucine-rich glioma-inactivated protein 1 antibody-associated limbic encephalitis[J]. Epilepsy Behav, 2017, 77:90-95. [25] Morano A, Fanella M, Giallonardo AT, Di Bonaventura C. Faciobrachial dystonic seizures:the borderland between epilepsy and movement disorders[J]. Mov Disord Clin Pract, 2020, 7:228-229. [26] Mo J, Dong W, Cui T, Chen C, Shi W, Hu W, Zhang C, Wang X, Zhang K, Shao X. Whole-brain metabolic pattern analysis in patients with anti-leucine-rich glioma-inactivated 1(LGI1) encephalitis[J]. Eur J Neurol, 2022, 29:2376-2385. [27] Wesselingh R, Broadley J, Buzzard K, Tarlinton D, Seneviratne U, Kyndt C, Stankovich J, Sanfilippo P, Nesbitt C, D'Souza W, Macdonell R, Butzkueven H, O'Brien TJ, Monif M. Electroclinical biomarkers of autoimmune encephalitis[J]. Epilepsy Behav, 2022, 128:108571. [28] Steriade C, Mirsattari SM, Murray BJ, Wennberg R. Subclinical temporal EEG seizure pattern in LGI1-antibody-mediated encephalitis[J]. Epilepsia, 2016, 57:e155-160. [29] Liu X, Han Y, Yang L, Wang B, Shao S, Feng Y, Pang Z, Du Y, Lin Y. The exploration of the spectrum of motor manifestations of anti-LGI1 encephalitis beyond FBDS[J]. Seizure, 2020, 76:22-27. [30] Baysal-Kirac L, Tuzun E, Altindag E, Ekizoglu E, Kinay D, Bilgic B, Tekturk P, Baykan B. Are there any specific EEG findings in autoimmune epilepsies[J]? Clin EEG Neurosci, 2016, 47:224-234. [31] Gibson LL, McKeever A, Coutinho E, Finke C, Pollak TA. Cognitive impact of neuronal antibodies:encephalitis and beyond[J]. Transl Psychiatry, 2020, 10:304. |